Product image of Lenalidomida Combix (Lenalidomide) supplied by GNH India

Lenalidomida Combix

Active Ingredient:
Lenalidomide
Origin:
EU

Lenalidomida Combix (Lenalidomide)

Lenalidomide, the active ingredient in Lenalidomida Combix, is an immunomodulatory agent (IMiD) presented as an oral formulation for oral use. It is employed in the treatment of certain blood cancers and related disorders, particularly in adult patients who require disease‑modifying therapy.
GNH India supplies Lenalidomida Combix as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Manufacturer / TM Owner

Laboratorios Combix, S.L.U.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lenalidomide is used in hematologic malignancies and related disorders, targeting abnormal cell growth and immune dysregulation.

  • Multiple myeloma: improves progression‑free survival and overall response rates in patients with relapsed or refractory disease.
  • Myelodysplastic syndromes with del(5q): reduces transfusion dependence and corrects cytopenias.
  • Mantle cell lymphoma: contributes to disease control when combined with other agents in relapsed settings.

How It Works

  • Lenalidomide binds to the cereblon component of the CRL4 E3 ubiquitin ligase complex, altering substrate specificity and promoting ubiquitination and proteasomal degradation of the transcription factors Ikaros and Aiolos. This leads to anti‑angiogenic effects, modulation of cytokine production, enhanced natural killer and T‑cell activity, and direct inhibition of malignant cell proliferation.

Side Effects

Adverse reactions may vary in frequency and severity.

Common Side Effects

  • Fatigue: persistent tiredness affecting daily activities.
  • Neutropenia: reduced neutrophil count increasing infection risk.
  • Thrombocytopenia: lowered platelet levels leading to easy bruising.
  • Diarrhea: loose stools that may require hydration.
  • Rash: mild skin eruptions or itching.
  • Constipation: difficulty passing stool.

Serious or Rare Side Effects

  • Venous thromboembolism: blood clots in deep veins or lungs.
  • Severe neutropenia: profound immune suppression with fever.
  • Severe thrombocytopenia: risk of serious bleeding.
  • Secondary primary malignancies: emergence of new cancers.
  • Stevens‑Johnson syndrome: severe skin reaction requiring urgent care.
  • Hepatic failure: marked liver enzyme elevation and dysfunction.

Precautions & Warnings

Lenalidomide requires careful monitoring and specific safety measures.

  • Pregnancy: contraindicated; teratogenic risk mandates effective contraception for both sexes.
  • Blood counts: regular CBC monitoring to detect neutropenia or thrombocytopenia.
  • Thromboembolism risk: assess need for prophylactic anticoagulation in high‑risk patients.
  • Renal/hepatic impairment: dose adjustment may be needed based on organ function.
  • Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Lenalidomide may interact with several drug classes, requiring vigilance.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase drug exposure.
  • Strong CYP3A4 inducers (e.g., rifampin): may reduce therapeutic levels.
  • Anticoagulants (e.g., warfarin): heightened bleeding risk.

Moderate Interactions (Monitor Closely)

  • Antiplatelet agents (e.g., aspirin): additive bleeding potential.
  • Live vaccines: reduced efficacy and possible infection.
  • Other immunomodulatory agents: may amplify immunosuppression.

Frequently Asked Questions

Lenalidomida Combix contains lenalidomide and is indicated for the treatment of multiple myeloma, myelodysplastic syndromes with the del(5q) chromosomal abnormality, and mantle cell lymphoma. These are hematologic cancers where the drug helps control disease progression and improve patient outcomes.

Lenalidomide binds to cereblon, a component of the CRL4 E3 ubiquitin ligase complex, altering its activity. This triggers degradation of transcription factors Ikaros and Aiolos, leading to anti‑angiogenic effects, modulation of cytokine release, enhanced immune cell function, and direct inhibition of malignant cell growth.

The specific dose of Lenalidomida Combix is determined by the prescribing physician based on the patient’s diagnosis, disease stage, renal function, and other clinical factors. Only a qualified healthcare professional should set the dosing regimen.

Lenalidomida Combix is classified as Pregnancy Category X because it is known to cause fetal harm. It should not be used by pregnant women, and effective contraception is required for both men and women of reproductive potential. Breastfeeding is not recommended while on therapy.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lenalidomide belongs to the immunomodulatory drug class and offers a distinct mechanism compared with proteasome inhibitors or monoclonal antibodies. It is often used in combination regimens and may provide benefits such as oral administration and specific activity against del(5q) MDS, while safety profiles differ among agents.

Store Lenalidomida Combix at ambient temperature, below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains sealed until use.

Lenalidomida Combix is taken orally, usually with water. The exact schedule—such as daily dosing or specific cycle days—must be prescribed by a qualified clinician and followed exactly as instructed.

Serious risks include venous thromboembolism, severe neutropenia or thrombocytopenia, secondary primary malignancies, and rare but severe skin reactions like Stevens‑Johnson syndrome. Patients should be monitored closely for signs of infection, bleeding, or unusual skin changes.

Lenalidomida Combix should not be used by individuals who are pregnant, have uncontrolled infections, have severe renal or hepatic impairment without dose adjustment, or have a known hypersensitivity to lenalidomide or any of the product’s excipients.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lenalidomide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT